-
-
The UK Tobacco and Vapes Bill: a historic opportunity Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-18
No Abstract
-
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-17 Jackie Duda
No Abstract
-
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment Thorax (IF 9.0) Pub Date : 2024-12-18 Gabriel Lavoie, Imran Howell, James Melhorn, Catherine Borg, Laura Bermejo-Sanchez, Jack Seymour, Maisha F. Jabeen, Anastasia Fries, Gareth Hynes, Ian D Pavord, Nayia Petousi, Timothy SC Hinks
Macrolides reduce exacerbations when added to inhaled therapy in severe asthma. However, there is little published evidence for effectiveness in patients treated with biologics. We conducted a retrospective audit of all patients who started azithromycin while on biologics in our centre. Compared with those that did not start azithromycin, these individuals had more exacerbations and a phenotype of
-
Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience Thorax (IF 9.0) Pub Date : 2024-12-16 Wenjun Ye, Wenhai Fu, Caichen Li, Jianfu Li, Shan Xiong, Bo Cheng, Bin Xu, Qixia Wang, Yi Feng, Peiling Chen, Jianxing He, Wenhua Liang
Background Limited research exists on screening thresholds for low-dose CT in detecting malignant pure ground-glass lung nodules (pGGNs) in the Chinese population. Materials and methods A retrospective analysis of the Guangzhou Lung-Care programme was conducted, retrieving average transverse diameter, location, histopathology, frequency and follow-up intervals. Diagnostic performances for ‘lung cancers’
-
Short-term effects of home-based pulmonary rehabilitation during outpatient-managed exacerbations of COPD: a randomised controlled trial Thorax (IF 9.0) Pub Date : 2024-12-16 Ana Machado, Cíntia Dias, Cátia Paixão, António Pedro Gonçalves, Chris Burtin, Alda Marques
Background Uncertainty exists about the beneficial effects of delivering pulmonary rehabilitation (PR) during exacerbations of chronic obstructive pulmonary disease (ECOPD). This study explored the short-term effects and self-reported impact of a home-based PR programme for people with outpatient-managed ECOPD. Methods We conducted a mixed-methods randomised controlled trial in people with outpatient-managed
-
Hospitalised older adults with community-acquired pneumonia and sepsis have dysregulated neutrophil function but preserved glycolysis Thorax (IF 9.0) Pub Date : 2024-12-16 Frances Grudzinska, Aduragbemi A Faniyi, Kylie B R Belchamber, Celine Chen, Robert Stockley, Alice Jasper, Dhruv Parekh, Elizabeth Sapey, Aaron Scott, David R Thickett
Objective Community-acquired pneumonia (CAP) is a leading cause of hospitalisation in older adults and is associated with a high likelihood of adverse outcomes. Given the ageing population and lack of therapeutic advances in CAP, new strategies to manage the burden of this disease are needed. Neutrophil dysfunction has been widely demonstrated in CAP and is associated with poor outcomes. We hypothesised
-
Obstructive sleep apnoea syndrome and future risk of dementia among individuals managed in UK general practice Thorax (IF 9.0) Pub Date : 2024-12-16 Jingya Wang, Anuradhaa Subramanian, Neil Cockburn, Jingyi Xiao, Krishnarajah Nirantharakumar, Shamil Haroon
Background Obstructive sleep apnoea syndrome (OSAS) has been recognised as a potential risk factor for cognitive decline, yet its precise relationship with dementia remains uncertain. This study aimed to determine the risk of dementia among individuals with and without OSAS. Methods Data derived from 2.3 million adults (aged ≥18 years) were extracted from the Clinical Practice Research Datalink (2000–2022)
-
Limitations in the Study of Vitamin D Supplementation and Severe Asthma Exacerbations. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Kuan-Po Cheng,James Cheng-Chung Wei
-
The Struggle Continues: Improving Outcomes for Surrogate Decision-Makers after the Intensive Care Unit. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Katherine R Courtright,James Downar
-
Reply to Cheng and Wei: Limitations in the Study of Vitamin D Supplementation and Severe Asthma Exacerbations. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Franziska J Rosser,Yueh-Ying Han,Juan C Celedón
-
Is Disease Stability an Attainable COPD Treatment Goal? Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Dave Singh,MeiLan K Han,Surya P Bhatt,Marc Miravitlles,Chris Compton,Stefanie Kolterer,Tharishini Mohan,Suneal K Sreedharan,Lee Tombs,David M G Halpin
Chronic obstructive pulmonary disease (COPD) is a heterogenous lung condition characterized by progressive airflow obstruction. Despite advancements in diagnosis and treatment, the disease burden remains high; although clinical trials have shown improvements in outcomes such as exacerbations, quality of life, and lung function, improvement may not be attainable for many patients. For patients who do
-
Air Hunger Far Exceeds Dyspnea Sense of Effort During Mechanical Ventilation and a Weaning Trial. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Amal Jubran,Franco Laghi,Brydon J B Grant,Martin J Tobin
RATIONALE No systematic investigation into dyspnea in patients receiving prolonged ventilation (>21 days) after recovering from critical-illness has been published. OBJECTIVES To determine magnitude, nature and pathophysiological basis of dyspnea during an unassisted-breathing trial in prolonged-ventilation patients. METHODS Dyspnea intensity and descriptor selection were investigated in 27 prolonged-ventilation
-
Nasal High Flow to Modulate Dyspnea in Orally Intubated Patients. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Valentine Le Stang,Mélodie Graverot,Antoine Kimmoun,Marie-Cécile Niérat,Maxens Decavèle,Thomas Similowski,Alexandre Demoule,Martin Dres
RATIONALE High flow therapy reduces dyspnea in acute respiratory failure but the underlying mechanisms are not fully elucidated. OBJECTIVES To compare dyspnea, airway occlusion pressure (P0.1) and inspiratory work with and without nasal high flow (NHF, FiO2 21%, temperature 31°C) in intubated patients under pressure support ventilation and during a spontaneous breathing trial (SBT). METHODS Dyspnea
-
Lung Function in the Second Decade of Life in Children after Early HIV Diagnosis and ART Initiation. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Andre G Gie,Marieke M van der Zalm,Eric D McCollum,Sara Browne,Mark F Cotton,Pierre Goussard,Steve Innes
-
Inbuilt Errors: A Call for Standardized Definitions. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Aman Pande,Philppe Haouzi
-
Editorial Position of the American Thoracic Society Journal Family on the Evolving Role of Artificial Intelligence in Scientific Research and Review. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Nitin Seam,Sanjay H Chotirmall,Fernando J Martinez,Andrew J Halayko,Michael O Harhay,Stephanie D Davis,Paul T Schumacker,Robert M Tighe,Kristin M Burkart,Colin Cooke
-
Prevalence and Clinical Correlates of Radiologically Detected Coronary Artery Disease in COPD: A Cross-Sectional Observational Study. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-16 Mairi A MacLeod,Kristopher D Knott,James P Allinson,Lydia J Finney,Dexter J Wiseman,Andrew I Ritchie,Aaron Braddy-Green,Sam Barlett-Pestell,Ralph Lopez,Logan Sun,Philippa Webb,Paras Dalal,Michael Rubens,Simon Davies,Dorian O Haskard,Anand Devaraj,Gavin C Donaldson,Ramzi Y Khamis,Edward D Nicol,Jadwiga A Wedzicha
RATIONALE Unrecognised coronary artery disease (CAD) may contribute to adverse outcomes in chronic obstructive pulmonary disease (COPD). Improved identification of at-risk groups could inform better preventative care. We aimed to evaluate the burden and relationships of radiologically detectable CAD in COPD, establish frequency of occult disease, and examine potential cardiovascular screening methods
-
Neighborhood Level Socioeconomic Disadvantage and Adherence to Guidelines for the Evaluation of Patients with Incidentally Detected Pulmonary Nodules. Chest (IF 9.5) Pub Date : 2024-12-16 Jacob M Abrahams,Beth Creekmur,Janet Shin Lee,In-Lu Amy Liu,Mayra Macias,Michael K Gould
BACKGROUND The management of incidental pulmonary nodules is guided by recommendations set forth by the Fleischner Society. While most pulmonary nodules are benign, timely and evidence-based follow-up can reduce morbidity and mortality. There are known socioeconomic disparities for engagement with recommended cancer screenings, however it is unclear whether disparities exist for follow-up of incidentally
-
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-12 Margaux M I Meslé, Jeremy Brown, Marc-Alain Widdowson, Richard G Pebody
No Abstract
-
Incorrect interpretation of the role of COVID-19 vaccination boosters in saving lives Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-12 Tijl De Bie
No Abstract
-
New management pathways for follow-up of CPAP-treated sleep apnoea patients including digital medicine and multimodal telemonitoring Thorax (IF 9.0) Pub Date : 2024-12-12 Jean-Louis Pépin, Sébastien Baillieul, Sébastien Bailly, Renaud Tamisier
Background The ever-increasing number of patients diagnosed with obstructive sleep apnoea (OSA) and treated by long-term continuous positive airway pressure (CPAP) overstretches conventional follow-up pathways. New approaches to the management of CPAP-treated patient follow-up are needed to strike a balance between remote monitoring through digital technologies and in-person patient-healthcare-professional
-
Pneumococcal pneumonia trends in adults hospitalised with community-acquired pneumonia over 10 years (2013–2023) and the role of serotype 3 Thorax (IF 9.0) Pub Date : 2024-12-12 Louise Lansbury, Tricia M McKeever, Hannah Lawrence, Harry Pick, Vadsala Baskaran, Rochelle Edwards-Pritchard, Laura Matthews, Helen Bailey, Deborah Ashton, Lesley Bendall, Chamira Rodrigo, Priya Daniel, David Litt, Seyi Eletu, Hanshi Parmar, Carmen Sheppard, Shamez N Ladhani, Caroline Trotter, Wei Shen Lim
Background With higher valency pneumococcal vaccines on the horizon and new adult immunisation strategies under discussion, we aimed to evaluate the contribution of individual pneumococcal serotypes to the burden of pneumococcal community-acquired pneumonia (CAP). Over 10 years, trends in pneumococcal pneumonia epidemiology in adults hospitalised with CAP were assessed. The risk factors and severity
-
Tuberculosis in adult migrants in Europe: a TBnet consensus statement. Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-13 Heinke Kunst,Berit Lange,Olga Hovardovska,Annabelle Bockey,Dominik Zenner,Aase B Andersen,Sally Hargreaves,Manish Pareek,Jon S Friedland,Chrsitain Wejse,Graham Bothamley,Lorenzo Guglielmetti,Dima Chesov,Simon Tiberi,Alberto Matteelli,Anna M Mandalakas,Jan Heyckendorf,Johannes Eimer,Akanksha Malhotra,Javier Zamora,Anca Vasiliu,Christoph Lange,
INTRODUCTION Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. Migrants' risk of tuberculosis (TB) differs by reasons for migration, socioeconomic status, mode of travel and TB risk in transit, TB incidence and healthcare provision in country of origin. Despite advances
-
How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes. Chest (IF 9.5) Pub Date : 2024-12-13 Fariba M Donovan,George R Thompson,Janis E Blair,Royce H Johnson,Josh Malo,Waseem Albasha,Stephanie G Worrell,Staci E Beamer,Kavitha Yaddanapudi,John N Galgiani,Neil M Ampel
Coccidioidomycosis (CM), caused by the dimorphic fungi Coccidioides immitis (C. immitis) and C. posadasii, is recognized as an increasing threat both nationally and worldwide. This is in large part secondary to the expanding range of Coccidioides spp. and increased international travel to endemic regions. The majority of individuals exposed to airborne Coccidioides organisms do not need medical attention
-
Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: a Multicenter Study. Chest (IF 9.5) Pub Date : 2024-12-13 Otaola Maria,Vasarmidi Eirini,Ottaviani Sébastien,Gutierrez Marwin,Dalpiaz Marina Soledad,Gaser Adrian,Juge Pierre-Antoine,Bertolazzi Chiara,Avgoustidis Nestor,Skiadas Christos,Della Maggiora Maricel,Orausclio Paola,Quintana-Rodriguez Alan,Debray Marie-Pierre,Perez Cepas Barbara,Schneeberger Emilce,Sidiropoulos Prodromos,Lloves Schenone Nicolas,Rosemffet Marcos,Marciano Sebastian,Antoniou Katerina
BACKGROUND The screening strategy for interstitial lung disease (ILD) in rheumatoid arthritis patients is currently debated. While high-resolution computed tomography (HRCT) is the gold standard for diagnosing ILD, its systematic use as a screening tool is not yet recommended. The role of lung ultrasound (LUS) in assessing ILD has been previously explored. RESEARCH QUESTION What is the performance
-
The effects of low-dose morphine on sleep and breathlessness in COPD: A randomized trial. Chest (IF 9.5) Pub Date : 2024-12-13 Thomas James Altree,Alison Pinczel,Barbara Toson,Kelly Loffler,Anna Hudson,Jim Zeng,Simon Proctor,Ganesh Naik,Sutapa Mukherjee,Peter Catcheside,Andrew Somogyi,David Currow,Danny Eckert
BACKGROUND Low-dose morphine may be prescribed to reduce chronic breathlessness in chronic obstructive pulmonary disease (COPD). Recent subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD. The effects of morphine during sleep in COPD have not been objectively investigated. This study aimed to objectively
-
Reply to: Is there a kindling effect in COPD exacerbations? Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Halpin, D. M. G., Heatley, H., Price, D.
Extract We thank A.I. Papaioannou and K. Bartziokas for their interest in our study of the relationship between exacerbation history and blood eosinophil count prior to a diagnosis of COPD and the risk of subsequent exacerbations [1]. As they point out, it is well known that in patients with an established diagnosis and on maintenance treatment, the prior exacerbation history is the best predictor
-
The lung that rules the heart Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Vonk Noordegraaf, A., Bogaard, H. J.
Extract Throughout time, and in many cultures, the heart has been considered the centre of the human body. This core (Coeur!) organ dominates all other parts of the body and rules our emotions; its functioning determines the difference between life and death. Arguably, the lungs are of less importance and deserve less consideration. In reality, the heart and lungs are anatomically and functionally
-
Genes take the lead: genetic testing becomes the gold standard for diagnosing primary ciliary dyskinesia Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Shapiro, A. J., Thornton, C. S.
Extract Primary ciliary dyskinesia (PCD) is a rare, inherited disorder characterised by abnormal ciliary structure or function, leading to impaired mucociliary clearance. The condition primarily affects the respiratory system, where dysfunctional cilia fail to effectively move mucus, microorganisms and particles out of the airways, resulting in chronic respiratory infections, bronchiectasis and rhino-sinusitis
-
Bacterial misappropriation of host glucose in pneumococcal pneumonia Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Russell, C. D., Dockrell, D. H.
Extract Pneumococcal pneumonia remains an important clinical problem. Globally, Streptococcus pneumoniae is the organism responsible for the largest proportion of lower respiratory tract infections and associated deaths [1]. Serotype replacement driven by vaccination programmes, non-response to vaccination in some individuals, and inequitable global availability of vaccines and treatment all contribute
-
Is there a kindling effect in COPD exacerbations? Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Papaioannou, A. I., Bartziokas, K.
Extract We have read with great interest the article from Halpin et al. [1] showing that a single moderate COPD exacerbation in the year prior to COPD diagnosis significantly increases the risk of future exacerbations over the next 12 months, while more frequent or severe exacerbations prior to diagnosis are associated with a higher risk.
-
The modified Baveno classification for obstructive sleep apnoea: development and evaluation based on the ESADA database Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Matthes, S., Treml, M., Grote, L., Hedner, J., Zou, D., Bonsignore, M. R., Pepin, J.-L., Bailly, S., Ryan, S., McNicholas, W. T., Schiza, S. E., Verbraecken, J., Pataka, A., Sliwinski, P., Basoglu, O. K., Lombardi, C., Parati, G., Randerath, W. J., the ESADA study group
Background The "Baveno classification" replaced the apnoea–hypopnoea index (AHI) with symptoms and comorbidities for treatment indication in obstructive sleep apnoea (OSA). This study evaluates a modified Baveno classification which adds a validated cardiovascular disease (CVD) risk score and acknowledges severe breathing disturbances. Method OSA patients from the European Sleep Apnoea Database (ESADA)
-
Treating sleep disordered breathing for cardiovascular outcomes: observational and randomised trial evidence Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Bradley, T. D., Logan, A. G., Floras, J. S.
Sleep disordered breathing (SDB) is considered a risk factor for cardiovascular disease (CVD). Obstructive sleep apnoea (OSA) can be treated with continuous positive airway pressure (CPAP), and central sleep apnoea (CSA), in patients with heart failure with reduced ejection fraction (HFrEF), by peak flow-triggered adaptive servo-ventilation. Presently, there is equipoise as to whether treating SDB
-
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Hermann, E. A., Sun, Y., Hoffman, E. A., Allen, N. B., Ambale-Venkatesh, B., Bluemke, D. A., Carr, J. J., Kawut, S. M., Prince, M. R., Shah, S. J., Smith, B. M., Watson, K. E., Lima, J. A. C., Barr, R. G.
Background Lung structure and cardiac structure and function are associated cross-sectionally. The classic literature suggests relationships of airways disease to cor pulmonale and emphysema to reduced cardiac output (CO) but longitudinal data are lacking. Methods The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study was a multicentre longitudinal COPD case–control study of participants 50–79 years
-
Pathogenic variants in CFAP46, CFAP54, CFAP74 and CFAP221 cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Wohlgemuth, K., Hoersting, N., Koenig, J., Loges, N. T., Raidt, J., George, S., Cindric, S., Schramm, A., Biebach, L., Lay, S., Dougherty, G. W., Olbrich, H., Pennekamp, P., Dworniczak, B., Omran, H.
Background Primary ciliary dyskinesia is a rare genetic disorder caused by insufficient mucociliary clearance leading to chronic airway infections. The diagnostic guideline of the European Respiratory Society primarily recommends an evaluation of the clinical history (e.g. by the PICADAR prediction tool), nasal nitric oxide production rate measurements, high-speed videomicroscopy analysis of ciliary
-
Detection of M. tuberculosis DNA in peripheral blood mononuclear cells of tuberculosis contacts does not associate with blood RNA signatures for incipient tuberculosis Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Rosenheim, J., Abebe, M., Belay, M., Tulu, B., Tayachew, D., Tegegn, M., Younis, S., Jolliffe, D. A., Aseffa, A., Ameni, G., Reece, S. T., Noursadeghi, M., Martineau, A. R.
Extract Human exposure to Mycobacterium tuberculosis (Mtb) is thought to result in a spectrum of outcomes, including bacillary clearance, quiescent Mtb infection, incipient tuberculosis (TB), subclinical TB and active TB [1]. Incipient TB – defined as a prolonged asymptomatic phase of early disease preceding clinical presentation as active disease [2] – may be distinguished from quiescent Mtb infection
-
Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Akkerman, O. W., Migliori, G. B., Falzon, D., Garcia-Basteiro, A. L., Kanchar, A., Konstantynovska, O., Eyuboglu, F. O., Duarte, R.
Extract Transmission continues to drive the tuberculosis (TB) and drug-resistant TB epidemics, making infection control an essential component for public health agencies worldwide [1–3]. Transmission of TB is complex, influenced by factors linked to patient behaviour, the form of disease, the exposed individual, the microbe and the environment [3–6]. Each year, more than 10 million people develop TB
-
Microenvironmental acidification by pneumococcal sugar consumption fosters barrier disruption and immune suppression in the human alveolus Eur. Respir. J. (IF 16.6) Pub Date : 2024-12-12 Fatykhova, D., Fritsch, V. N., Siebert, K., Methling, K., Lalk, M., Busche, T., Kalinowski, J., Weiner, J., Beule, D., Bertrams, W., Kohler, T. P., Hammerschmidt, S., Löwa, A., Fischer, M., Mieth, M., Hellwig, K., Frey, D., Neudecker, J., Rueckert, J. C., Toennies, M., Bauer, T. T., Graff, M., Tran, H.-L., Eggeling, S., Gruber, A. D., Antelmann, H., Hippenstiel, S., Hocke, A. C.
Streptococcus pneumoniae is the most common causative agent of community-acquired pneumonia worldwide. A key pathogenic mechanism that exacerbates severity of disease is the disruption of the alveolar–capillary barrier. However, the specific virulence mechanisms responsible for this in the human lung are not yet fully understood. In this study, we infected living human lung tissue with Strep. pneumoniae
-
-
Missed Opportunities for Lung Cancer Screening among Behavioral Health Patients with Elevated Cigarette Smoking Rates: Lung Cancer Screening and Behavioral Health. Chest (IF 9.5) Pub Date : 2024-12-12 Anastasia Rogova,Lisa M Lowenstein,Lorraine R Reitzel,Kathleen Casey,Robert J Volk
Annual lung cancer screening using low dose computed tomography (LDCT) effectively reduces mortality from lung cancer and is recommended for persons who are at high risk of developing the disease. The utilization of the lung cancer screening, however, has remained low. Due to significantly higher cigarette smoking rates, patients with behavioral health disorders (those living with mental illness and/or
-
How Glasgow's 1957 tuberculosis screening programme could help countries today Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-10 Peter Ranscombe
No Abstract
-
Caring for our interlocutors on the threshold of life and death Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-10 Magdalena Zegarra Chiappori
No Abstract
-
Pulmonary Arterial Inflammatory Myofibroblastic Tumor in an Adult. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-11 Ling Zhang,Ling Zhao,Min Liu
-
Promoting Prevention and Targeting Remission of Asthma A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Chest (IF 9.5) Pub Date : 2024-12-11 Milos Jesenak,Dr Anna Bobcakova,Ratko Djukanovic,Mina Gaga,Nicola A Hanania,Liam G Heaney,Ian Pavord,Santiago Quirce,Dr Dermot Ryan,Wytske Fokkens,Dr Diego Conti,Peter W Hellings,Glenis Scadding,Elizabeth Van Staeyen,Leif H Bjermer,Zuzana Diamant
TOPIC IMPORTANCE Asthma is a common multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes/endotypes and the availability of targeted biologic treatment options, a substantial proportion of patients remains uncontrolled with risk of exacerbations, requiring systemic corticosteroids, and progressive disease
-
Cost-related nonadherence to medication among people with asthma in the United States: findings that reinforce the relevance of history and healthcare reform Thorax (IF 9.0) Pub Date : 2024-12-09 Emily L Graul, Christer Janson
Asthma affects over 20 million (8%) of adults in the United States (US) each year.1 2 As with many chronic conditions, poor control can be attributed to low medication adherence and a reduced quality of life, and can translate into a high burden on the healthcare system and economy.3 4 Of importance is cost-related medication nonadherence, as people face heavy financial barriers to accessing US healthcare
-
Cost-related non-adherence to medications among adults with asthma in the USA, 2011–2022 Thorax (IF 9.0) Pub Date : 2024-12-09 Chun-Tse Hung, Steven R Erickson, Chung-Hsuen Wu
Background Uncontrolled asthma is possibly caused by medication non-adherence, and financial hardship can be a major contributor to non-adherence. Since economic conditions and asthma management have changed over time, a comprehensive investigation of cost-related medication non-adherence (CRN) among adults with asthma is crucial. Objective To evaluate trends, prevalence and determinants of CRN, and
-
Two thoracic surgeries and no diagnosis: is it lung cancer? Thorax (IF 9.0) Pub Date : 2024-12-07 Daniella Draicchio, Alexander Fox, Louise Haine, Robert Berg, Judith Hampson
A 69-year-old never-smoker was referred to a lung cancer assessment clinic in June 2022 with 4 weeks of exertional breathlessness, haemoptysis and fever, persisting despite three antibiotic courses. Medical history included a kyphoplasty and paroxysmal atrial fibrillation (PAF) requiring radiofrequency catheter ablations in July 2019 and February 2022. He had a previous episode of fever and haemoptysis
-
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data Thorax (IF 9.0) Pub Date : 2024-12-07 Alex E Henney, David R Riley, Theresa J Hydes, Matthew Anson, Gema H Ibarburu, Frederick Frost, Uazman Alam, Daniel J Cuthbertson
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are treatments for type 2 diabetes (T2D). Beyond glucose-lowering and cardiorenal protection, these drugs may protect against pneumonia and sepsis. Aims This study assesses the impact of SGLT2i and GLP-1 RAs on the risk of incident pneumonia and severe sepsis. Methods A retrospective
-
Beyond glycaemic control: reduced pneumonia and sepsis risk with GLP-1 RAs and SGLT2 inhibitors in patients with type 2 diabetes Thorax (IF 9.0) Pub Date : 2024-12-07 Ramin Rezaeianzadeh, Mohsen Sadatsafavi
As of 2021, 537 million adults are living with diabetes, globally. This is expected to reach 800 million in 20 years.1 Patients with diabetes live with a significantly heightened risk of morbidity and mortality from various causes.2 Among such causes are infections. Diabetes is associated with a significantly increased risk of infections like pneumonia and sepsis, due to immune system impairments from
-
Virtual reality anatomy trainer turns teaching endobronchial ultrasound inside-out. Chest (IF 9.5) Pub Date : 2024-12-09 Melissa L New,Tristan J Huie,Dru Claar,Timothy Amass,Ryan A Peterson,Max McGrath,Nicholas Jacobson,Anna Neumeier,Darlene Nelson
BACKGROUND Traditional approaches for learning anatomy for curvilinear endobronchial ultrasound (EBUS) require learners to mentally visualize structures relative to the position of the bronchoscope. Virtual reality (VR) can demonstrate anatomy from the perspective of bronchoscopic tools. RESEARCH QUESTION Does the use of a VR anatomy trainer for teaching EBUS-associated anatomy improve procedural performance
-
Evaluating tezepelumab for COPD: a missed target or unmet potential? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-06 Mario Cazzola, Paola Rogliani, Maria Gabriella Matera
No Abstract
-
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-06 Dave Singh, Christopher E Brightling, Klaus F Rabe, MeiLan K Han, Stephanie A Christenson, M Bradley Drummond, Alberto Papi, Ian D Pavord, Nestor A Molfino, Gun Almqvist, Ales Kotalik, Åsa Hellqvist, Monika Gołąbek, Navreet S Sindhwani, Sandhia S Ponnarambil
BackgroundTezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, which has shown increased expression in patients with chronic obstructive pulmonary disease (COPD) compared with healthy individuals. We aimed to assess the efficacy and safety of tezepelumab in patients with moderate to very severe COPD despite receiving triple inhaled therapy. MethodsCOURSE was a double-blind
-
Surfactant protein B deficiency: the RespiRare cohort Thorax (IF 9.0) Pub Date : 2024-12-06 Manon Fleury, Céline Delestrain, Léa Roditis, Caroline Perisson, Marie-Catherine Renoux, Caroline Thumerelle, Ralph Epaud, Camille Fletcher, Nouha Jedidi, Aurore Coulomb L'Hermine, Harriet Corvol, Hubert Ducou le Pointe, Pascale Fanen, Chiara Sileo, Camille Louvrier, Alix de Becdelievre, Marie Legendre, Nadia Nathan
Childhood interstitial lung diseases (chILD) are rare and usually severe disorders. Among them, very rare cases of surfactant protein (SP)-B deficiencies have been reported so far and are usually associated with fatal forms of chILD. The RespiRare network allows the collection of precise phenotypic and genotypic information. This study that reports a series of 11 SP-B-deficient patients underscores
-
Advanced MicroRNA delivery for lung inflammatory therapy: surfactant protein A controls cellular internalisation and degradation of extracellular vesicles Thorax (IF 9.0) Pub Date : 2024-12-06 Miji Kim, Sujeong Park, Nayoung Lee, Dohyun Kim, Dongwoo Kim, Yang Jin, Seon-Jin Lee, Jung Joo Hong, Heedoo Lee
Introduction Alveolar macrophages (AMs) are the first line of defence against pathogens that initiate an inflammatory response in the lungs and exhibit a strong affinity for surfactant protein A (SP-A). Extracellular vesicles (EVs) have emerged as a promising drug delivery platform due to their minimal cytotoxicity. However, precise targeting of specific cell types and the rapid lysosomal degradation
-
GOLD COPD report: 2025 update Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Priya Venkatesan
No Abstract
-
Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Job F M van Boven, Richard W Costello, Kit C B Roes, Guy G Brusselle, Kjeld Hansen, Jerry A Krishnan, Christopher E Brightling, Nicolas Roche, Salman Siddiqui, Bruce J Kirenga, Hilary Pinnock, Amy H Y Chan
Digital technologies (eg, smart inhalers, wearables, and sensors) allow for remote, objective, granular, and non-invasive data collection, making them attractive for research evaluating interventions in airways diseases with variable trajectories, such as asthma. Such technologies offer the opportunity to move towards decentralised clinical trials that are done partly or fully outside the classic clinical
-
A career development programme for women at an academic medical centre Lancet Respir. Med. (IF 38.7) Pub Date : 2024-12-05 Marika Orlov, Sarah L Rhoads, Kelsey Hills-Dunlap, Sunita Sharma, Sarah Jolley
No Abstract
-
Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD Thorax (IF 9.0) Pub Date : 2024-12-05 Tjeerd van der Veer, Eleni-Rosalina Andrinopoulou, Gert-Jan Braunstahl, Jean Paul Charbonnier, Victor Kim, Rudolfs Latisenko, David A Lynch, Harm Tiddens
In this cohort study involving 9399 current and former smokers from the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease study, we assessed the relationship between artificial intelligence-quantified mucus plugs on chest CTs and all-cause mortality. Our results revealed a significant positive association, particularly for those with COPD GOLD stages 1–4, with HRs of 1.18 for 1–2 mucus-obstructed
-
C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study. Am. J. Respir. Crit. Care Med. (IF 19.3) Pub Date : 2024-12-06 Brigitta Derendinger,Tessa K Mochizuki,Danaida Marcelo,Deepa Shankar,Wilson Mangeni,Hanh Nguyen,Seda Yerlikaya,William Worodria,Charles Yu,Nhung Viet Nguyen,Devasahayam Jesudas Christopher,Grant Theron,Patrick Pj Phillips,Payam Nahid,Claudia M Denkinger,Adithya Cattamanchi,Christina Yoon
Rationale: C-reactive protein (CRP)-based tuberculosis (TB) screening is recommended for people with HIV (PWH). However, its performance among people without HIV and in diverse settings is unknown. Objectives: In a multi-country study, we aimed to determine whether CRP meets the minimum accuracy targets (sensitivity ≥90%, specificity ≥70%) for an effective TB screening test. Methods/Measurements: Consecutive